Individuals prescribed GLP-1 receptor agonists, SGLT2 inhibitors, or neither were compared for the incidence of four obesity-related hematologic malignancies using a Cox proportional hazards model. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.